
106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the ...
Background Despite modern HER2-directed treatment options, relevant recurrence risk persists in patients with extensive local disease and/or lack of pathologic complete response (pCR) to neoadjuvant therapy. Neratinib is approved in Europe for extended …